{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:23:24Z","timestamp":1789190604304,"version":"build-2803163510"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T00:00:00Z","timestamp":1580947200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T00:00:00Z","timestamp":1580947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s12185-020-02829-6","type":"journal-article","created":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T05:27:51Z","timestamp":1580966871000},"page":"496-511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Molecular basis of clonal evolution in multiple myeloma"],"prefix":"10.1007","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7249-6418","authenticated-orcid":false,"given":"Yusuke","family":"Furukawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,6]]},"reference":[{"key":"2829_CR1","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/jjco\/hyv088","volume":"45","author":"M Hori","year":"2015","unstructured":"Hori M,  Matsuda T,  Shibata A,  Katanoda K,  Sobue T,  Nishimoto H et al. Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the monitoring of Cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol.  2015;45:884\u2013891","journal-title":"Jpn J Clin Oncol."},{"key":"2829_CR2","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia.  2014;28:1122\u20131128","journal-title":"Leukemia"},{"key":"2829_CR3","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2016.380","volume":"31","author":"R Fonseca","year":"2017","unstructured":"Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, Richardson P. Trends in overall survival and costs of multiple myeloma, 2000\u20132014. Leukemia.  2017;31:1915\u20131921","journal-title":"Leukemia"},{"key":"2829_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41408-018-0155-7","volume":"8","author":"SZ Usmani","year":"2018","unstructured":"Usmani SZ, Hoering A, Cavo M, San Miguel J, Goldschimdt H, Hajek R. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma\u2014an IMWG research project. Blood Cancer J. 2018;8:123","journal-title":"Blood Cancer J."},{"key":"2829_CR5","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1038\/bcj.2015.79","volume":"5","author":"S Ozaki","year":"2015","unstructured":"Ozaki S, Handa H,  Saitoh T,  Murakami H, Itagaki M,  Asaoku H. Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese society of myeloma. Blood Cancer J. 2015;5:e349","journal-title":"Blood Cancer J."},{"key":"2829_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"LB Alexandrov S Nik-Zainal DC Wedge 2013 Signatures of mutational processes in human cancer. Nature. 500:415\u2013421","journal-title":"Nature"},{"key":"2829_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","volume":"471","author":"MA Chapman","year":"2011","unstructured":"Chapman MA, Lawrence MS, Keats JJ, et al.  Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471:467\u2013472","journal-title":"Nature"},{"key":"2829_CR8","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1182\/blood-2012-01-405977","volume":"120","author":"JB Egan","year":"2012","unstructured":"Egan JB, Shi C-X, Tembe W, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012;120:1060\u20131066","journal-title":"Blood"},{"key":"2829_CR9","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","volume":"120","author":"JJ Keats","year":"2012","unstructured":"Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120:1067\u20131076","journal-title":"Blood"},{"key":"2829_CR10","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1182\/blood-2012-03-412981","volume":"120","author":"BA Walker","year":"2012","unstructured":"Walker BA, Wardell CP, Melchor L, et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood. 2012;120:1077\u20131086","journal-title":"Blood"},{"key":"2829_CR11","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/leu.2012.287","volume":"27","author":"N Weston-Bell","year":"2013","unstructured":"Weston-Bell N, Gibson J, John M, Ennis S, Pfeifer S, Cezard T, et al. Exome sequencing in tracking clonal evolution in multiple myeloma following therapy. Leukemia. 2013;27:1188\u20131191","journal-title":"Leukemia"},{"key":"2829_CR12","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/leu.2012.226","volume":"27","author":"F Magrangeas","year":"2013","unstructured":"Magrangeas F, Avet-Loiseau H, Gouraud W, et al. Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia. 2013;27:473\u2013481","journal-title":"Leukemia"},{"key":"2829_CR13","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/leu.2013.199","volume":"28","author":"BA Walker","year":"2014","unstructured":"Walker BA, Wardell CP, Melchor L, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 2014;28:384\u2013390","journal-title":"Leukemia"},{"key":"2829_CR14","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1038\/ncomms3997","volume":"5","author":"N Bolli","year":"2014","unstructured":"Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997","journal-title":"Nat Commun."},{"key":"2829_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr JG, Stojanov P, Carter LS, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25:91\u2013101","journal-title":"Cancer Cell"},{"key":"2829_CR16","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1038\/leu.2014.13","volume":"28","author":"L Melchor","year":"2014","unstructured":"Melchor L, Brioli A, Wardell CP, Murison A, Potter NE, Kaiser MF, et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia. 2014;28:1705\u20131715","journal-title":"Leukemia"},{"key":"2829_CR17","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","volume":"33","author":"BA Walker","year":"2015","unstructured":"Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, et al. Mutational spectrum, copy number changes, and outcome: Results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33:3911\u20133920","journal-title":"J Clin Oncol."},{"issue":"13","key":"2829_CR18","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","volume":"128","author":"N Weinhold","year":"2016","unstructured":"Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, Tytarenko R, et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016;128(13):1735\u20131744","journal-title":"Blood"},{"key":"2829_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/leu.2017.197","volume":"32","author":"A Lagan\u00e0","year":"2018","unstructured":"Lagan\u00e0 A, Perumal D, Melnekoff D, Readhead B, Kidd BA, Leshchenko V, et al. Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma. Leukemia. 2018;32:120\u2013130","journal-title":"Leukemia"},{"key":"2829_CR20","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","volume":"132","author":"BA Walker","year":"2018","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132:587\u2013597","journal-title":"Blood"},{"key":"2829_CR21","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1038\/s41375-018-0037-9","volume":"32","author":"N Bolli","year":"2018","unstructured":"Bolli N, Biancon G, Moarii M, Gimondi S, Li Y, de Philippis C, et al. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018;32:2604\u20132616","journal-title":"Leukemia"},{"key":"2829_CR22","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3324\/haematol.2018.202200","volume":"104","author":"JR Jones","year":"2019","unstructured":"Jones JR, Weinhold N, Ashby C, Walker BA, Wardell C, Pawlyn C, et al. Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica. 2019;104:1440\u20131450","journal-title":"Haematologica"},{"key":"2829_CR23","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1182\/blood-2012-12-471888","volume":"121","author":"BA Walker","year":"2013","unstructured":"Walker BA, Wardell CP, Johnson DC, et al. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood.  2013;121:3413\u20133419","journal-title":"Blood"},{"key":"2829_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/leu.2017.204","volume":"32","author":"A Lakshman","year":"2018","unstructured":"Lakshman A, Alhaj Moustafa M, Rajkumar SV, Dispenzieri A, Gertz MA, Buadi FK, et al. Natural history of t(11;14) multiple myeloma. Leukemia. 2018;32:131\u2013138","journal-title":"Leukemia"},{"key":"2829_CR25","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1182\/blood-2014-07-584268","volume":"125","author":"C Pawlyn","year":"2015","unstructured":"Pawlyn C, Melchor L, Murison A, Wardell CP, Brioli A, Boyle EM, et al. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood. 2015;125:831\u2013840","journal-title":"Blood"},{"key":"2829_CR26","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1182\/blood-2015-06-650242","volume":"126","author":"M-L Chretien","year":"2015","unstructured":"Chretien M-L, Corre J, Lauwers-Cances V, Magrangeas F, Cleynen A, Yon E, et al. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? Blood. 2015;126:2713\u20132719","journal-title":"Blood"},{"key":"2829_CR27","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1038\/s41467-019-11680-1","volume":"10","author":"F Maura","year":"2019","unstructured":"Maura F, Bolli N, Angelopoulos N, Dawson KJ, Leongamornlert D, Martincorena I, et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun. 2019;10:3835","journal-title":"Nat Commun."},{"key":"2829_CR28","first-page":"275","volume":"8","author":"N Tsuyama","year":"2019","unstructured":"Tsuyama N, Abe Y, Yanagi A, Yanai Y, Sugai M, Katafuchi A, et al. Induction of t(11;14) IgH enhancer\/promoter-cyclin D1 gene translocation using CRISPR\/Cas9. Oncol Lett. 2019;8:275\u2013282","journal-title":"Oncol Lett."},{"key":"2829_CR29","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41375-018-0300-0","volume":"33","author":"Z Xie","year":"2019","unstructured":"Xie Z, Chooi JY, Toh SHM, Yang D, Basri NB, Ho YS, Chng WJ MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells. Leukemia. 2019;33:739\u2013748","journal-title":"Leukemia"},{"key":"2829_CR30","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1158\/2159-8290.CD-18-0083","volume":"9","author":"J Zhang","year":"2019","unstructured":"Zhang J, Lee YR, Dang F, Gan W, Menon AV, Katon JM, et al. PTEN methylation by NSD2 controls cellular sensitivity to DNA damage. Cancer Discov. 2019;9:1306\u20131323","journal-title":"Cancer Discov."},{"key":"2829_CR31","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s12185-016-2048-5","volume":"104","author":"Y Furukawa","year":"2016","unstructured":"Furukawa Y, Kikuchi J. Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma. Int J Hematol. 2016;104:281\u2013292","journal-title":"Int J Hematol."},{"key":"2829_CR32","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1172\/JCI80325","volume":"125","author":"J Kikuchi","year":"2015","unstructured":"Kikuchi J, Koyama D, Wada T, Izumi T, Hofgaard PO, Bogen B, Furukawa Y. Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma. J Clin Invest. 2015;125:4375\u20134390","journal-title":"J Clin Invest."},{"key":"2829_CR33","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1111\/cas.14109","volume":"110","author":"T Murase","year":"2019","unstructured":"Murase T, Ri M, Narita T, Fujii K, Masaki A, Iida S, Inagaki H. Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma. Cancer Sci. 2019;110:2600\u20132606","journal-title":"Cancer Sci."},{"key":"2829_CR34","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.3324\/haematol.2017.163766","volume":"102","author":"A Mikulasova","year":"2017","unstructured":"Mikulasova A, Wardell CP, Murison A, Boyle EM, Jackson GH, Smetana J, Kufova Z, et al. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica. 2017 ;102:1617\u20131625","journal-title":"Haematologica"},{"key":"2829_CR35","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1158\/0008-5472.CAN-17-3115","volume":"78","author":"N van Nieuwenhuijzen","year":"2018","unstructured":"van Nieuwenhuijzen N, Spaan I, Raymakers R, Peperzak V, et al. From MGUS to multiple myeloma, a paradigm for clonal evolution of premalignant cells. Cancer Res. 2018;78:2449\u20132456","journal-title":"Cancer Res."},{"key":"2829_CR36","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1182\/blood-2016-02-698092","volume":"128","author":"KM Kort\u00fcm","year":"2016","unstructured":"Kort\u00fcm KM, Mai EK, Hanafiah NH, Shi CX, Zhu YX, Bruins L, et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and ras pathway genes. Blood. 2016;128:1735\u20131744","journal-title":"Blood"},{"key":"2829_CR37","doi-asserted-by":"publisher","first-page":"6997","DOI":"10.1038\/ncomms7997","volume":"6","author":"BA Walker","year":"2015","unstructured":"Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015;6:6997","journal-title":"Nat Commun."},{"key":"2829_CR38","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","volume":"9","author":"N Bolli","year":"2018","unstructured":"Bolli N, Maura F, Minvielle S, Gloznik D, Szalat R, Fullam A, et al. Genomic patterns of progression in smoldering multiple myeloma. Nat Commun.  2018;9:3363","journal-title":"Nat Commun"},{"key":"2829_CR39","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2017.345","volume":"32","author":"F Maura","year":"2018","unstructured":"Maura F, Petljak M, Lionetti M, Cifola I, Liang W, Pinatel E, et al. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dysclasias and multiple myeloma cell lines. Leukemia. 2018;32:1044\u20131048","journal-title":"Leukemia"},{"key":"2829_CR40","doi-asserted-by":"publisher","first-page":"7122","DOI":"10.1038\/s41598-019-43575-y","volume":"9","author":"H Yamazaki","year":"2019","unstructured":"Yamazaki H, Shirakawa K, Matsumoto T, Hirabayashi S, Murakawa Y, Kobayashi M, et al. Endogenous APOBEC3B overexpression constitutively generates DNA substitution and deletions in myeloma cells Sci. Rep. 2019;9:7122","journal-title":"Sci. Rep."},{"key":"2829_CR41","doi-asserted-by":"publisher","first-page":"8307","DOI":"10.1038\/s41598-019-44407-9","volume":"9","author":"T Matsumoto","year":"2019","unstructured":"Matsumoto T, Shirakawa K, Yokoyama M, Fukuda H, Sarca AD, Koyabu s, et al. Protein kinase A inhibits tumor mutator APOBEC3B through phosphorylation Sci. Rep. 2019;9 8307","journal-title":"Sci. Rep."},{"key":"2829_CR42","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41408-019-0221-9","volume":"9","author":"PH Hoang","year":"2019","unstructured":"Hoang PH, Comish AJ, Dobbins SE, Kaiser M, Houlston RS. Mutational process contributing to the development of multiple myeloma. Blood Cancer. J. 2019 ;9:60","journal-title":"Blood Cancer J."},{"key":"2829_CR43","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/leu.2014.70","volume":"28","author":"M Affer","year":"2014","unstructured":"Affer M, Chesi M, Chen WG, Keats JJ, Demchenko YN, Roschke AV, et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia. 2014;28:1725\u20131735","journal-title":"Leukemia"},{"key":"2829_CR44","doi-asserted-by":"publisher","first-page":"e600","DOI":"10.1038\/bcj.2017.83","volume":"7","author":"M Binder","year":"2017","unstructured":"Binder M, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, Lacy MQ, et al. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. Blood Cancer J. 2017;7:e600","journal-title":"Blood Cancer J."},{"key":"2829_CR45","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.blre.2018.11.003","volume":"34","author":"D Vr\u00e1bel","year":"2019","unstructured":"Vr\u00e1bel D, Pour L, Sevc\u00edkov\u00e1 S. The impact of NF-kB signaling on pathogenesis and current treatment strategies in multiple myeloma. Blood Rev. 2019;34: 56\u201366","journal-title":"Blood Rev."},{"key":"2829_CR46","doi-asserted-by":"publisher","first-page":"602","DOI":"10.3109\/10428194.2014.924116","volume":"56","author":"IC Glitza","year":"2015","unstructured":"Glitza IC, Lu G, Shah R, Bashir Q, Shah N, Champlin RE, et al. Chromosome 8q241\/c-MYC abnormality: a marker for high-risk myeloma Leuk. Lymphoma 2015;56 :602\u2013607","journal-title":"Leuk Lymphoma"},{"key":"2829_CR47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/leu.2017.179","volume":"32","author":"V Shah","year":"2018","unstructured":"Shah V, Sherborne AL, Walker BA, Johnson DC, Boyle EM, Ellis S, et al. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia. 2018;32:102\u2013110","journal-title":"Leukemia"},{"key":"2829_CR48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood-2018-04-842880","volume":"132","author":"L Resche","year":"2018","unstructured":"Resche L, Angtuaco EJ, Alpe TL, Gershner GH, McDonald JE, Samant RS, et al. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood. 2018;132:59\u201366","journal-title":"Blood"},{"key":"2829_CR49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","volume":"33","author":"BA Walker","year":"2019","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, et al. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33:159\u2013170","journal-title":"Leukemia"},{"key":"2829_CR50","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3389\/fonc.2018.00665","volume":"8","author":"KK Jovanovic","year":"2019","unstructured":"Jovanovic KK, Escure G, Demonchy J, Willaume A, Van de Wyngaert Z, Farhat M, et al. Deregulation and targeting of TP53 pathway in multiple myeloma. Front Oncol. 2019;8:665","journal-title":"Front. Oncol."},{"key":"2829_CR51","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3324\/haematol.2010.023697","volume":"95","author":"L Lod\u00e9","year":"2010","unstructured":"Lod\u00e9 L, Eveillard M, Trichet V, Soussi T, Wuill\u00e8me S, Richebourg S, et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica. 2010;95:1973\u20131976","journal-title":"Haematologica"},{"key":"2829_CR52","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.3324\/haematol.2017.168872","volume":"102","author":"S Thanendrarajan","year":"2017","unstructured":"Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, et al. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017;102:e364\u2013e367","journal-title":"Haematologica"},{"key":"2829_CR53","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/ncb3380","volume":"18","author":"D Walerych","year":"2016","unstructured":"Walerych D, Lisek K, Sommaggio R, Piazza S, Ciani Y, Dalla E, et al. Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. Nat Cell Biol. 2016;18:897\u2013909","journal-title":"Nat Cell Biol."},{"key":"2829_CR54","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1038\/bcj.2017.76","volume":"7","author":"M Chin","year":"2017","unstructured":"Chin M, Sive JI, Allen C, Roddie C, Chavda SJ, Smith D, et al. Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival. Blood Cancer J. 2017;7:e610","journal-title":"Blood Cancer J."},{"key":"2829_CR55","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1182\/blood-2018-10-880831","volume":"133","author":"A Thakurta","year":"2019","unstructured":"Thakurta A, Ortiz M, Blecua P, Towfic F, Corre J, Serbina NV, et al. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. Blood. 2019;133:1217\u20131221","journal-title":"Blood"},{"key":"2829_CR56","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1182\/bloodadvances.2018028530","volume":"3","author":"A Lakshman","year":"2019","unstructured":"Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, et al. Impact of acquired del(17p) in multiple myeloma. Blood Adv. 2019;3:1930\u20131938","journal-title":"Blood Adv."},{"key":"2829_CR57","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/s41375-019-0512-y","volume":"33","author":"S Branford","year":"2019","unstructured":"Branford S, Kim DDH, Apperley JF, et al. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia Leukemia. 2019;33:1835\u20131850","journal-title":"Leukemia"},{"key":"2829_CR58","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1158\/1078-0432.CCR-12-3461","volume":"19","author":"K Todoerti","year":"2013","unstructured":"Todoerti K, Agnelli L, Fabris S, Lionetti M, Tuana G, Mosca L, et al. Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. Clin Cancer Res. 2013;19:3247\u20133258","journal-title":"Clin Cancer Res."},{"key":"2829_CR59","doi-asserted-by":"publisher","first-page":"17543","DOI":"10.18632\/oncotarget.4028","volume":"6","author":"I Cifola","year":"2015","unstructured":"Cifola I, Lionetti M, Pinatel E, Todoerti K, Mangano E, Pietrelli A, et al. Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational process. Oncotarget. 2015;6:17543\u201317558","journal-title":"Oncotarget"},{"key":"2829_CR60","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s10147-015-0837-0","volume":"20","author":"Y Furukawa","year":"2015","unstructured":"Furukawa Y, Kikuchi J. Molecular pathogenesis of multiple myeloma. Int J Clin Oncol. 2015;20:413\u2013422","journal-title":"Int J Clin Oncol."},{"key":"2829_CR61","doi-asserted-by":"publisher","first-page":"4634","DOI":"10.1158\/1078-0432.CCR-12-3866","volume":"19","author":"B H\u00e9braud","year":"2013","unstructured":"H\u00e9braud B, Caillot D, Corre J, et al. The translocation t(4;14) can be present only in minor subclones in multiple myeloma. Clin Cancer Res. 2013;19:4634\u20134637","journal-title":"Clin Cancer Res."},{"key":"2829_CR62","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrc.2017.63","volume":"17","author":"C Pawlyn","year":"2017","unstructured":"Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer. 2017;17:543\u2013556","journal-title":"Nat Rev Cancer"},{"key":"2829_CR63","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41375-018-0206-x","volume":"33","author":"AK Dutta","year":"2019","unstructured":"Dutta AK, Fink JL, Grady JP, Morgan GJ, Mullighan CG, To LB, et al. Subclonal evolution in disease progression from MGUS\/SMM to multiple myeloma is characterized by clonal stability. Leukemia. 2019;33:457\u2013468","journal-title":"Leukemia"},{"key":"2829_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21873\/anticanres.13074","volume":"39","author":"L Lacina","year":"2019","unstructured":"Lacina L, Coma M, Dvor\u00e1nkov\u00e1 B, Kodet O, Melegov\u00e1 N, G\u00e1l P, Smetana K Jr. Evolution of cancer progression in the context of Darwinism. Anticancer Res. 2019;39:1\u201316","journal-title":"Anticancer Res."},{"key":"2829_CR65","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1017\/S0016672308009531","volume":"89","author":"T Ohta","year":"2007","unstructured":"Ohta T, Kimura M. A model of mutation appropriate to estimate the number of electrophoretically detectable alleles in a finite population. Genet Res. 2007;89:367\u2013370","journal-title":"Genet Res."},{"key":"2829_CR66","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/ng.3489","volume":"48","author":"MJ Williams","year":"2016","unstructured":"Williams MJ, Werner B, Barnes CP, Graham TA, Sottoriva A. Identification of neutral tumor evolution across cancer types. Nat Genet. 2016;48:238\u2013244","journal-title":"Nat Genet."},{"key":"2829_CR67","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nm.4353","volume":"23","author":"CA Eide","year":"2017","unstructured":"Eide CA, Druker BJ. Understanding cancer from the stem cells up. Nat Med. 2017;23:656\u2013657","journal-title":"Nat Med."},{"key":"2829_CR68","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1182\/blood-2016-06-723494","volume":"128","author":"K Mitani","year":"2016","unstructured":"Mitani K, Nagata Y, Sasaki K, Yoshida K, Chiba K, Tanaka H, et al. Somatic mosaicism in chronic myeloid leukemia in remission. Blood. 2016 ;128:2863\u20132866","journal-title":"Blood"},{"key":"2829_CR69","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1182\/blood-2016-11-750612","volume":"130","author":"DC Johnson","year":"2017","unstructured":"Johnson DC, Lenive O, Mitchell J, Jackson G, Owen R, Drayson M, et al. Neutral tumor evolution in myeloma is associated with poor prognosis. Blood. 2017;130:1639\u20131643","journal-title":"Blood"},{"key":"2829_CR70","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","volume":"8","author":"L Rasche","year":"2017","unstructured":"Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, et al.  Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017;8:268","journal-title":"Nat Commun."},{"key":"2829_CR71","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1182\/blood-2015-12-686782","volume":"127","author":"M Raab","year":"2016","unstructured":"Raab M, Lehners N, Xu J, Ho AD, Schirmacher P, Goldschmidt H, Andrulis M. Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition. Blood. 2016;127:2155\u20132157","journal-title":"Blood"},{"key":"2829_CR72","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41409-018-0264-8","volume":"54","author":"WI Gonsalves","year":"2019","unstructured":"Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transpl. 2019;54:353\u2013367","journal-title":"Bone Marrow Transpl."},{"key":"2829_CR73","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266\u20132275","journal-title":"Leukemia"},{"key":"2829_CR74","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/PPO.0000000000000350","volume":"25","author":"P Kapoor","year":"2019","unstructured":"Kapoor P, Rajkumar SV. Smoldering multiple myeloma: to treat or not to treat. Cancer J. 2019;25:65\u201371","journal-title":"Cancer J."},{"key":"2829_CR75","doi-asserted-by":"publisher","first-page":"5599","DOI":"10.2147\/CMAR.S205623","volume":"11","author":"AL Zhao","year":"2019","unstructured":"Zhao AL, Shen KN, Wang JN, Huo LQ, Li J, Cao XX, et al. Early or deferred treatment of smoldering multiple myeloma: a meta-analysis on randomized controlled studies. Cancer Manag Res. 2019;11:5599\u20135611","journal-title":"Cancer Manag Res."},{"key":"2829_CR76","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","volume":"24","author":"G Ledergor","year":"2018","unstructured":"Ledergor G, Weiner A, Zada M, Wang SY, Cohen YC, Gatt ME, et al. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat Med. 2018;24:1867\u20131876","journal-title":"Nat Med."},{"key":"2829_CR77","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1182\/blood-2012-06-436220","volume":"121","author":"A Chaidos","year":"2013","unstructured":"Chaidos A, Barnes CP, Cowan G, May PC, Melo V, Hatjiharissi S, et al. Clinical drug resistance linked to interconvertible phenotypes and functional states of tumor-propagating cells in multiple myeloma. Blood. 2013;121:318\u2013328","journal-title":"Blood"},{"key":"2829_CR78","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1038\/s41375-019-0392-1","volume":"33","author":"L Herviou","year":"2019","unstructured":"Herviou L, Jourdan M, Martinez A-M, Cavalli G, Moreaux J. EZH2 is overexpressed in transitional preplasmablasts and is involved in human plasma cell differentiation. Leukemia. 2019;33:2047\u20132060","journal-title":"Leukemia"},{"key":"2829_CR79","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12185-016-2016-0","volume":"104","author":"M Ri","year":"2016","unstructured":"Ri M. Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma. Int J Hematol. 2016;104: 273\u2013 280","journal-title":"Int J Hematol."},{"key":"2829_CR80","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1002\/cti2.1007","volume":"7","author":"N Nikesitch","year":"2018","unstructured":"Nikesitch N, Lee JM, Ling S, Roberts TL. Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance. Clin Transl Immunology 2018;7:e1007","journal-title":"Clin Transl Immunology"},{"key":"2829_CR81","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","volume":"24","author":"C Leung-Hagesteijn","year":"2013","unstructured":"Leung-Hagesteijn C, Erdmann N, Cheung G, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 2013;24:289\u2013304","journal-title":"Cancer Cell"},{"key":"2829_CR82","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1038\/s41598-019-39672-7","volume":"9","author":"T Bagratuni","year":"2019","unstructured":"Bagratuni T, Sklirou AD, Kastritis E, Liacos CI, Spilioti C, Eleutherakis-Papaiakovou E, et al. Toll-like receptor 4 activation promotes multiple myeloma cell growth and survival via suppression of the endoplasmic reticulum stress factor chop. Sci Rep. 2019;9:3245","journal-title":"Sci Rep."},{"key":"2829_CR83","doi-asserted-by":"publisher","first-page":"e124698","DOI":"10.1172\/jci.insight.124698","volume":"4","author":"J Kellner","year":"2019","unstructured":"Kellner J, Wallace C, Liu B, Li Z. Definition of a multiple myeloma progenitor population in mice driven by forced expression of XBP1s JCI Insight 2019 ;4: e124698","journal-title":"JCI Insight"},{"key":"2829_CR84","doi-asserted-by":"publisher","first-page":"28096","DOI":"10.18632\/oncotarget.8581","volume":"7","author":"M Jourdan","year":"2016","unstructured":"M Jourdan M Cren P Schafer 2016 Differential effects of lenalidomide during plasma cell differentiation. Oncotarget. 7:28096\u201328111","journal-title":"Oncotarget"},{"key":"2829_CR85","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279\u20133289","journal-title":"J Clin Oncol."},{"key":"2829_CR86","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamaoncol.2018.2961","volume":"4","author":"F Gay","year":"2018","unstructured":"Gay F, Jackson G, Rosi\u00f1ol L, Holstein SA, Moreau P, Spada S, et al. Maintenance treatment and survival in patients with myeloma A systematic review and network meta-analysis. JAMA Oncol. 2018;4:1389\u20131397","journal-title":"JAMA Oncol."},{"key":"2829_CR87","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/leu.2017.256","volume":"32","author":"R Chakraborty","year":"2018","unstructured":"Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, et al. Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. Leukemia. 2018;32:712\u2013718","journal-title":"Leukemia"},{"key":"2829_CR88","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","volume":"20","author":"GH Jackson","year":"2019","unstructured":"Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:57\u201373","journal-title":"Lancet Oncol."},{"key":"2829_CR89","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s12185-018-2543-y","volume":"109","author":"S Fuchida","year":"2019","unstructured":"Fuchida S, Sunami K, Matsumoto M, Okumura H, Murayama T, Miyamoto T, et al. A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma. Int J Hematol. 2019;109:107\u2013114","journal-title":"Int J Hematol."},{"key":"2829_CR90","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41375-019-0383-2","volume":"33","author":"G Barosi","year":"2019","unstructured":"Barosi G, Gale RP. Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma? Leukemia. 2019;33:588\u2013596","journal-title":"Leukemia"},{"key":"2829_CR91","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1158\/0008-5472.CAN-17-2446","volume":"78","author":"J Kikuchi","year":"2018","unstructured":"Kikuchi J, Kuroda Y, Koyama D, Osada N, Izumi T, et al.  Myeloma cells are activated in bone marrow microenvironment by the CD180\/MD-1 complex which senses lipopolysaccharide. Cancer Res. 2018;78:1766\u20131778","journal-title":"Cancer Res"},{"key":"2829_CR92","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1182\/blood-2014-02-557819","volume":"124","author":"YX Zhu","year":"2014","unstructured":"Zhu YX, Braggio E, Shi CX, Kortuem KM, Bruins LA, Schmidt JE, et al. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood. 2014;124:536\u2013545","journal-title":"Blood"},{"key":"2829_CR93","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13045-016-0354-2","volume":"9","author":"M Pourabdollah","year":"2016","unstructured":"Pourabdollah M, Bahmanyar M, Atenafu EG, Reece D, Hou J, Chang H. High IKZF1\/3 protein expression is a favorable prognostic factor for survival of relapsed\/refractory multiple myeloma patients treated with lenalidomide. J Hematol Oncol. 2016;9:123","journal-title":"J Hematol Oncol."},{"key":"2829_CR94","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/leu.2017.60","volume":"31","author":"C Touzeau","year":"2017","unstructured":"Touzeau C, Moreau P, Dumontet C. Monoclonal antibody therapy in multiple myeloma. Leukemia. 2017;31:1039\u20131047","journal-title":"Leukemia"},{"key":"2829_CR95","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/leu.2017.329","volume":"32","author":"CS Chim","year":"2018","unstructured":"Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018;32:252\u2013262","journal-title":"Leukemia"},{"key":"2829_CR96","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s12185-018-2405-7","volume":"107","author":"H Tamura","year":"2018","unstructured":"Tamura H. Immunopathogenesis and immunotherapy of multiple myeloma. Int J Hematol. 2018;107:278\u2013285","journal-title":"Int J Hematol."},{"key":"2829_CR97","doi-asserted-by":"publisher","first-page":"e2018014","DOI":"10.4084\/mjhid.2018.014","volume":"10","author":"M Taniwaki","year":"2018","unstructured":"Taniwaki M, Yoshida M, Matsumoto Y, Shimura K, Kuroda J, Kaneko H. Elotuzumab for the treatment of relapsed or refractory multiple myeloma, with special reference to its modes of action and SLAMF7 signaling. Mediterr J Hematol Infect Dis. 2018;10:e2018014","journal-title":"Mediterr J Hematol Infect Dis."},{"key":"2829_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2040620718822660","volume":"10","author":"LE Franssen","year":"2019","unstructured":"Franssen LE, Mutis T, Lokhorst HM, van de Donk NWCJ. Immunotherapy in myeloma: how far have we come? Ther Adv Hematol. 2019;10:1","journal-title":"Ther Adv Hematol."},{"key":"2829_CR99","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/ejh.13046","volume":"100","author":"M Pick","year":"2018","unstructured":"Pick M, Vainstein V, Goldschmidt N, Lavie D, Libster D, Gural A, et al. Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis. Eur J Haematol. 2018;100:494\u2013501","journal-title":"Eur J Haematol."},{"key":"2829_CR100","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","volume":"116","author":"DM Benson Jr","year":"2010","unstructured":"Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, et al. The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti\u2013PD-1 antibody. Blood. 2010;116:2286\u20132294","journal-title":"Blood"},{"key":"2829_CR101","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/leu.2012.213","volume":"27","author":"H Tamura","year":"2013","unstructured":"Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A, et al. Marrow stromal cells induce B7\u2013H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia. 2013;27:464\u2013472","journal-title":"Leukemia"},{"key":"2829_CR102","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/leu.2015.79","volume":"29","author":"B Paiva","year":"2015","unstructured":"Paiva B, Azpilikueta A Puig N, Ocio EM, Sharma R, et al. PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia. 2015;29:2110\u20132113","journal-title":"Leukemia"},{"key":"2829_CR103","doi-asserted-by":"publisher","first-page":"6655","DOI":"10.1158\/0008-5472.CAN-18-1781","volume":"78","author":"Y Fujiwara","year":"2018","unstructured":"Fujiwara Y, Sun Y, Torphy RJ, He J, Yanaga K, et al. Pomalidomide inhibits PD-L1 induction to promote antitumor immunity. Cancer Res. 2018;78:6655\u20136665","journal-title":"Cancer Res."},{"key":"2829_CR104","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1158\/2326-6066.CIR-19-0148","volume":"7","author":"AM Lesokhin","year":"2019","unstructured":"Lesokhin AM, Bal S, Badros AZ. Lessons learned from checkpoint blockade targeting PD-1 in multiple myeloma. Cancer Immunol Res. 2019;7:1224\u20131229","journal-title":"Cancer Immunol Res."},{"key":"2829_CR105","doi-asserted-by":"crossref","unstructured":"Kikuchi J, Hori M, Sorimachi N, Hagiwara S, Kuroda Y, Koyama D, et al. Soluble SLAMF7 promotes the growth of myeloma cells via hemophilic interaction with surface SLAMF7. Leukemia. 2020;34:180\u2013195.","DOI":"10.1038\/s41375-019-0525-6"},{"key":"2829_CR106","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.18632\/oncotarget.1049","volume":"4","author":"Z Xie","year":"2013","unstructured":"Xie Z, Gunaratne J, Cheong LL, Liu SC, Koh TL, Huang G, et al. Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in T(4;14) multiple myeloma. Oncotarget. 2013;4:1008\u20131018","journal-title":"Oncotarget"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02829-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-020-02829-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02829-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T01:14:17Z","timestamp":1612487657000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-020-02829-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,6]]},"references-count":106,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["2829"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-02829-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,6]]},"assertion":[{"value":"8 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"YF received research funding and honoraria from AbbVie Inc., Bristol\u2013Myers Squibb Co., Celgene Co., Janssen Pharmaceutical K.K. and Takeda Pharmaceutical Co. JK declares no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}